Using cell-free DNA for HCC surveillance and prognosis

Area of Science:

• Oncology
• Molecular Diagnostics
• Genetics

Background:

• Hepatocellular carcinoma (HCC) incidence is increasing globally, posing a significant health burden.
• Limited tissue access and tumor heterogeneity in HCC challenge traditional diagnostic methods.
• Circulating tumor DNA (ctDNA) analysis via liquid biopsy presents a minimally invasive alternative.

Purpose of the Study:

• To review recent advancements in the use of circulating cell-free DNA (cfDNA) for HCC detection and management.
• To highlight the potential of cfDNA profiling for early disease identification and treatment monitoring.
• To discuss the clinical utility of liquid biopsy in improving HCC surveillance strategies.

Main Methods:

• Review of current literature on liquid biopsy techniques in HCC.
• Analysis of studies focusing on cfDNA profiling for genetic and epigenetic alterations.
• Evaluation of methylation analyses of ctDNA for early HCC detection.

Main Results:

• Liquid biopsy, particularly cfDNA analysis, shows promise for non-invasive detection of HCC.
• Methylation profiling of ctDNA demonstrates potential for early detection in at-risk populations.
• Ongoing studies are validating assay performance in longitudinal cohorts.

Conclusions:

• Liquid biopsy is a rapidly evolving field with significant potential to enhance HCC surveillance and management.
• cfDNA analysis, especially through methylation biomarkers, may revolutionize early HCC detection.
• Further validation is required for widespread clinical implementation of liquid biopsy in HCC care.